GLP-1R agonists have demonstrated neuroprotective effects across a range of neurodegenerative disorders, with preclinical studies demonstrating efficacy in animal models of Alzheimer’s, Parkinson’s disease, stroke, and ischemia, likely mediated through a reduction in chronic inflammation, normalization of insulin and growth factor signaling, enhanced energy utilization, and mitochondrial protection. This evidence concerns the gene GLP1R and stroke disorder.